Characterization of Folate Receptor Alpha (FRα) Expression in Archival Tumor and Biopsy Samples in a Phase I Study of Mirvetuximab Soravtansine, a FRα-Targeting Antibody Drug Conjugate (ADC), in Relapsed Epithelial Ovarian Cancer Patients - ImmunoGen
  • Clinical Trials
  • Patients and Caregivers
  • Healthcare Professionals
  • Investors and Media
  • Careers

  • Who We Are
    • Board of Directors Executive Committee Our History
  • What We Do
    • Our Science Our Target Indications Our Pipeline Our Products Publications
  • How We Do It
    • Our Culture Careers
  • Who We Are
    • Overview
    • Board of Directors
    • Executive Committee
    • Our History
  • What We Do
    • Overview
    • Our Science
    • Our Target Indications
    • Our Pipeline
    • Publications
  • How We Do It
    • Overview
    • Our Culture
    • Careers
  • Patients and Caregivers
  • Healthcare Professionals
  • Investors and Media
  • Careers

Characterization of Folate Receptor Alpha (FRα) Expression in Archival Tumor and Biopsy Samples in a Phase I Study of Mirvetuximab Soravtansine, a FRα-Targeting Antibody Drug Conjugate (ADC), in Relapsed Epithelial Ovarian Cancer Patients

  • Contact Us
  • Privacy Policy
  • Usage Policy

© 2023 ImmunoGen, Inc., All Rights Reserved

ImmunoGen, the ImmunoGen logos, and TARGET A BETTER NOW are trademarks or registered trademarks of ImmunoGen, Inc.